GlassScriptPhysician profile
Elisavet Paplomata
NPI 1891927687
$21,469.88
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $2,180 · 2021: $11.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,720.39 | 2019 | |
| Pfizer INC. | $5,085.30 | 2019 | |
| Mylan Institutional INC. | $5,066.34 | 2019 | |
| Puma Biotechnology, INC. | $2,180.00 | 2020 | |
| R-Pharm US LLC | $1,322.65 | 2019 | |
| Tesaro, INC. | $83.28 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisavet Paplomata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.